A gene marker linked to longer survival in glioblastoma
Original title: ZIC3 expression identifies a developmental transcriptional axis in IDH-wildtype glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This came from looking back at stored tumor samples and records from people, not from testing a treatment.
The short version
glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary tumors with more activity of a gene called ZIC3 were linked to people living longer.
What was studied. Researchers looked at stored tumor samples and health records from 167 people with a common form of glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary called IDH-wildtype. Survival was studied in 161 of them. They checked whether the level of a gene called ZIC3 lined up with how people did.
What they found. People whose tumors had more ZIC3 activity lived longer overall. They also went longer before the tumor grew again. This link held up after the researchers took age, sex, radiation, and the drug temozolomide into account. Tumors with more ZIC3 showed patterns tied to normal brain cell growth. Tumors with less ZIC3 showed patterns tied to low oxygen and stress inside the tumor.
What this means, and what it doesn't
What it could mean: This may help doctors sort glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary into more useful groups. It could help explain why the same tumor type behaves so differently from person to person. It is a clue about the biology of the tumor, not a treatment.
What it doesn't mean: This does not mean there is a new treatment, and it is not a cure. No one in this study was given a new drug. The researchers looked back at data that had already been collected, so this cannot prove that ZIC3 is the reason some people lived longer. There is no ZIC3 test in everyday cancer care right now. Work like this is early, and it may take years of more research before it changes anything for patients.
Source: PubMed, August 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.